| Unique ID issued by UMIN | UMIN000003231 |
|---|---|
| Receipt number | R000003909 |
| Scientific Title | Phase I Study of Pemetrexed Combined with Carboplatin for Elderly Patients with Advanced Non-small Cell Lung Cancer |
| Date of disclosure of the study information | 2010/02/22 |
| Last modified on | 2015/02/27 09:36:29 |
Phase I Study of Pemetrexed Combined with Carboplatin for Elderly Patients with Advanced Non-small Cell Lung Cancer
Phase I Study of PEM/CBDCA for elderly NSCLC
Phase I Study of Pemetrexed Combined with Carboplatin for Elderly Patients with Advanced Non-small Cell Lung Cancer
Phase I Study of PEM/CBDCA for elderly NSCLC
| Japan |
Non-small-cell lung cancer
| Pneumology | Hematology and clinical oncology |
Malignancy
NO
To evaluate safety, feasibility and to determine the recommended dose of CBDCA+PEM for elderly patients with advanced NSCLC
Safety
Exploratory
Pragmatic
Phase I
To estimate maximum tolerated dose and determine the recommended dose
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Medicine |
Pemetrexed
Carboplatin
| 75 | years-old | <= |
| Not applicable |
Male and Female
1) Histologically or cytologically proven non-small-cell lung cancer.
2) Aged >= 75 years.
3) ECOG performance status: 0-1
4) Patient who has measurable lesion by RECIST.
5) No prior chemotherapy for NSCLC. Interval from previous treatment, of following, at enrollment;
(a) Surgery: more than 4 weeks after surgery.
(b) Radiation: more than 4 weeks after the thoracic irradiation or more than 2weeks after the last irradiation to the other organs.
6) No history of receiving chemotherapy against other concomitant malignancy.
7) Adequate organ functions;
(a) WBC >= 4,000/mm3 and Netrophile >= 2,000/mm3
(b) Hb >= 9.0 g/dL
(c) Plt >= 100,000/mm3
(d) T. Bil <= 1.5 g/dL
(e) AST and ALT, <= 100 U/L
(f) Serum creatinine <= 1.5 mg/dL and Ccr >= 45ml/min/body
(g) PaO2 >= 70 torr (at room)
8) Written informed consent.
9) Life expectancy >= 3 months
1) Patients with active concomitant malignancy.
2) Patients with massive pleural or pericardial effusion.
3) Patients with symptomatic brain metastasis.
4) Patients with diarrhea or ileus at enrollment.
5) Active lung disease such as interstitial pneumonia, idiopathic pulmonary fibrosis.
6) Patients with other clinically significant complications.
(a) uncontrollable cardiovascular disease.
(b) uncontrollable diabetes and hypertension.
(c) Active severe infections.
(d) History of active psychological disease.
7) Patients with steroid treatment.
8) Patients who had a history of severe drug allergy.
9) Inappropriate patients for this study judged by the physicians.
20
| 1st name | |
| Middle name | |
| Last name | Kazuhiko Yamada |
Kurume University School of Medicine
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine
67 Asahi-machi, Kurume, Fukuoka
0942-31-7560
kayamada@med.kurume-u.ac.jp
| 1st name | |
| Middle name | |
| Last name | Hiroaki Takeoka, Kazuhiko Yamada |
Kurume University School of Medicine
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine
67 Asahi-machi, Kurume, Fukuoka
0942-31-7560
kayamada@med.kurume-u.ac.jp
Division of Respirology, Neurology, and Rheumatology,
Department of Internal Medicine, Kurume University School of Medicine
Division of Respirology, Neurology, and Rheumatology,
Department of Internal Medicine, Kurume University School of Medicine
Self funding
NO
| 2010 | Year | 02 | Month | 22 | Day |
Published
Completed
| 2010 | Year | 02 | Month | 18 | Day |
| 2010 | Year | 02 | Month | 01 | Day |
| 2010 | Year | 02 | Month | 22 | Day |
| 2015 | Year | 02 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003909